Thousand Oaks, CA-headquartered pharmaceutical company Amgen, announced plans to invest $200 million in 2025 to establish its new technology and innovation center in Hyderabad, southern India. CEO Robert Bradway made this announcement during the site's inauguration on Monday, Feb 24, adding that significant additional investments are planned for future years....
India Grows in Importance as a Hub for Biopharmaceutical Manufacturing
India is growing in importance as a hub for biopharmaceutical manufacturing, particularly in the context of the proposed Biosecure Act in the United States. The Act aims to restrict U.S. biotech companies from working with Chinese firms, potentially driving more business towards Indian contract development and manufacturing organizations (CDMOs). A...
Lilly to Launch Diabetes Drug Mounjaro in India
Eli Lilly is planning to launch its blockbuster type 2 diabetes drug Mounjaro (tirzepatide) in India as early as next year, according to e Reuters. Mounjaro is currently under review by Indian health authorities, with Lilly having submitted data from its global clinical trials that included Indian patients. Tirzepatide, the...
India’s Biocon to Develop Weight Loss Biosimilar
Bangalore-based drugmaker Biocon, is developing its own version of Novo Nordisk's wildly popular weight-loss drug Wegovy in a bid to be a part of the exploding obesity treatment market that is forecast to reach at least $100 billion by 2030. The company's CEO Siddharth Mittal said they aim to be...
Eli Lilly Launches Drug for Psoriasis in India
Indianapolis, Indiana-headquartered Eli Lilly launched Copellor (Ixekizumab) in India to treat adults that have moderate-to-severe plaque psoriasis and who are candidates for systemic therapy or phototherapy. The drug will also be available for the treatment of adult patients with active psoriatic arthritis. Psoriasis is a chronic auto-immune disorder of the...
Eli Lilly Receives Emergency Authorization for Oral Covid Treatment
Eli Lilly of Indiana received permission for restricted emergency use from India's Central Drugs Standard Control Organization, for baricitinib in combination with remdesivir, for treatment of suspected or laboratory-confirmed coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. The company has...